RESUMO
PURPOSE: About 50%-90% of patients with brain metastases who receive radiation therapy experience cognitive impairment. This systematic review aims to gather credible sources of comprehensive information on the efficacy of memantine in preventing cognitive dysfunction. METHODS: A comprehensive review conducted in compliance with the PRISMA statement and systematic search was performed across five databases included PubMedâ, Embaseâ, Scopusâ, Cochrane Libraryâ, and ClinicalTrial.gov.in from inception until November 2021. RESULTS: A total of four eligible studies were selected in this review that included 1,444 patients with brain metastases who received radiation therapy (Intervention group [nâ¯=â¯729] and control group [nâ¯=â¯715]). Overall, three of the four studies reported some improvement in neurocognitive function in at least one or more parameters such as recall and recognition (Pâ¯=â¯.39, Pâ¯=â¯.10 and Pâ¯=â¯.05), verbal fluency (Pâ¯=â¯.03 and P < .0001), complex attention (Pâ¯=â¯.59) executive function (P = .92) and normal appearing white matter (Pâ¯=â¯.01) following memantine therapy compared to control group. Further, two of the four studies reported an improvement in the patients' quality of life following memantine therapy compared to the control group, and there was no significant difference in the toxicity profile of the interventional compared to the control group as reported from two studies. CONCLUSION: This review embraces the comprehensive evidence that the use of memantine therapy in patients with brain metastases to prevent radiation-induced neurocognitive dysfunction has a modest and statistically significant beneficial impact in improving quality of life and preserving some neurocognitive function without any complications. Pending the completion of additional ongoing studies, one can argue that memantine is a reasonable treatment to consider in patients with brain metastases while they receive whole brain radiation therapy.